Your browser doesn't support javascript.
loading
CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection.
Cheng, Jian; Liu, Zhao; Deng, Tian; Lu, Zhen; Liu, Maoxuan; Lu, Xiaoxu; Adeshakin, Funmilayo Oladunni; Yan, Dehong; Zhang, Guizhong; Wan, Xiaochun.
Affiliation
  • Cheng J; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China.
  • Liu Z; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China.
  • Deng T; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China.
  • Lu Z; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China.
  • Liu M; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China.
  • Lu X; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China.
  • Adeshakin FO; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China.
  • Yan D; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China.
  • Zhang G; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China. Electronic ad
  • Wan X; Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, PR China; Guangdong immune cell therapy engineering and technology research center (No. 2580 [2018]), PR China; Shenzhen BinD
Mol Immunol ; 129: 94-102, 2021 01.
Article in En | MEDLINE | ID: mdl-33223223
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytoskeleton / Antigens, CD / GTPase-Activating Proteins / Membranes Limits: Humans Language: En Journal: Mol Immunol Year: 2021 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cytoskeleton / Antigens, CD / GTPase-Activating Proteins / Membranes Limits: Humans Language: En Journal: Mol Immunol Year: 2021 Document type: Article Country of publication: